TSE:AUP - Aurinia Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$9.04 +0.21 (+2.38 %)
(As of 05/24/2019 04:00 PM ET)
Previous CloseC$8.83
Today's RangeC$8.83 - C$9.10
52-Week RangeC$6.61 - C$10.47
Volume44,486 shs
Average Volume70,432 shs
Market CapitalizationC$829.81 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

Receive AUP News and Ratings via Email

Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Technical & System Software
Sub-IndustryN/A
SectorComputer and Technology
CUSIPN/A
CIKN/A
Phone+1-250-7084272

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$463,000.00
Cash FlowC$1.71 per share
Book ValueC$1.57 per share

Profitability

Miscellaneous

Employees39
Market CapC$829.81 million
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable

Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (TSE:AUP) released its earnings results on Tuesday, March, 19th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.04. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.09 million. View Aurinia Pharmaceuticals' Earnings History.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Aurinia Pharmaceuticals.

What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

Press coverage about AUP stock has trended positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Allena Pharmaceuticals (ALNA), Lipocine (LPCN), Neovasc (NVCN), TOP SHIPS (TOPS), Bio-Path (BPTH), Coherus Biosciences (CHRS), CytRx (CYTR), Heat Biologics (HTBX) and Biopharmx (BPMX).

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 61)
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Neil Solomons M.D., Chief Medical Officer

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUP stock can currently be purchased for approximately C$9.04.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of C$829.81 million and generates C$463,000.00 in revenue each year. Aurinia Pharmaceuticals employs 39 workers across the globe.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.


MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/25/2019 by MarketBeat.com Staff

Featured Article: What is a trade deficit?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel